Press Releases May 08, 2024 Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress May 08, 2024 Innoviva to Participate in the BofA Securities Health Care Conference Apr 24, 2024 Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024 View all press releases Presentations & Events BofA Securities Health Care Conference May 15, 2024 at 12:20 PM EDT Listen to webcast View all presentations & events Form 8937 View Form 8937 - September 30, 2015 View Form 8937
May 08, 2024 Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress
Apr 24, 2024 Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024